GLOW Peptide Blend Explained: BPC-157, TB-500, GHK-Cu
What Is the GLOW Peptide Blend?
GLOW peptide blend is the name the peptide research community has given to a three-peptide combination: BPC-157, TB-500, and GHK-Cu. Rather than researchers ordering three separate vials, suppliers pre-combine them into a single lyophilized (freeze-dried) vial. Most commonly in a 5:1:1 ratio, meaning for every 50 mg of GHK-Cu, the blend contains 10 mg of BPC-157 and 10 mg of TB-500.
The name comes from the visible research interest in GHK-Cu’s role in skin and connective tissue remodeling, but the blend’s research scope extends well beyond skin. Spanning vascular, muscular, and connective-tissue research models.
The Three Peptides, Individually

BPC-157 (Body Protection Compound-157) is a synthetic peptide that researchers sequenced from a partial protein they identified in human gastric juice. Studies have examined its role in angiogenesis and fibroblast migration in tendon models (Chang et al., J Appl Physiol), nitric-oxide signaling, and broader musculoskeletal healing outcomes across the preclinical literature (2025 systematic review, 36 studies).
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein. Researchers study its role in actin regulation. The mechanism cells use to migrate, and have documented accelerated re-epithelialization and angiogenesis in cutaneous wound models (Malinda et al.), which explains why it appears frequently in systemic tissue-repair research alongside BPC-157.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine, a copper-binding tripeptide) occurs naturally in human plasma and declines with age. It has one of the deepest research literatures of the three: foundational work by Pickart and Margolina documents its effects on collagen, elastin, and glycosaminoglycan synthesis, along with broad gene-expression modulation.
Why These Three Peptides Are Combined



Each peptide’s research profile targets a different piece of the tissue-repair pathway:
| Peptide | Primary research focus |
|---|---|
| BPC-157 | Angiogenesis, gut/tendon models, inflammation signaling |
| TB-500 | Cell migration, systemic tissue models, actin regulation |
| GHK-Cu | Collagen/elastin synthesis, gene expression, copper-dependent enzyme activity |
Because BPC-157 and TB-500 both intersect with angiogenesis pathways, and GHK-Cu contributes on the structural/collagen side, researchers studying combined tissue-repair models often look at all three together rather than in isolation. No published human trial has evaluated the three-peptide combination as a single formulation. Researchers draw the rationale for combining them from the individual-compound literature, not from combined-blend trials.
Glow peptide Composition and Concentration Reference explained
A standard pre-blended GLOW vial (70 mg total) breaks down as:
- 50 mg GHK-Cu
- 10 mg BPC-157
- 10 mg TB-500
Reconstituting with 3.0 mL of bacteriostatic water yields an approximate total concentration of 23.3 mg/mL. Researchers working with lyophilized peptide blends generally reconstitute with bacteriostatic (not sterile) water when they need to store the solution for any length of time, and they keep the reconstituted vial refrigerated, out of light, and within the stability window the Certificate of Analysis (CoA) documents for that batch.
If you’d rather control the ratio yourself instead of using a fixed pre-blend, Peptide Bros offers a GLOW Bundle – BPC-157, TB-500, and GHK-Cu in three separate vials.

(This section covers general laboratory handling and solution-preparation math, it is not guidance for human administration.)
Handling and Storage
- Store lyophilized (unreconstituted) peptide at -20°C for long-term stability.
- Once reconstituted, refrigerate (not freeze) and avoid repeated freeze-thaw cycles, which degrade peptide structure.
- Always check the CoA for the specific batch, and verify purity and any contaminant testing (including heavy metals) before use in any research application.
- Use sterile technique when reconstituting to avoid microbial contamination of the vial.
What the Research Does and Doesn’t Show
It’s worth being direct about the state of the evidence: BPC-157 and TB-500 research is overwhelmingly preclinical (animal models, cell cultures) — a 2025 systematic review covering 36 studies found only one small human study on BPC-157 (12 patients, chronic knee pain) and no FDA approval or clinical safety data, and GHK-Cu has a mix of preclinical and some topical/dermatological human study data. No one has run dedicated published trials on the three-peptide combination itself. Suppliers and researchers extrapolate claims about the blend’s effects from single-compound studies rather than demonstrate them for the combination itself. Anyone evaluating this space should treat blend-specific benefit claims with real skepticism until combination-specific research exists.
Glow peptide blend FAQ
What ratio does GLOW peptide blend usually come in? Most commercial and research suppliers use a 5:1:1 ratio (GHK-Cu : BPC-157 : TB-500) and typically package it as 50mg/10mg/10mg per vial.
How do you reconstitute GLOW peptide blend? Researchers typically use bacteriostatic water and aim for a target concentration around 23.3 mg/mL — always calculate this per your specific vial’s total mg content.
Is GLOW peptide blend the same as buying BPC-157, TB-500, and GHK-Cu separately? Chemically, yes — it’s the same three peptides. The difference is convenience (one vial, one reconstitution, fixed ratio) versus flexibility (you set the ratio yourself). Peptide Bro’s GLOW Bundle ships BPC-157, TB-500, and GHK-Cu as three separate vials for exactly this reason.
Is GLOW peptide legal in Canada? Canadian suppliers sell research peptides including BPC-157, TB-500, and GHK-Cu under a research-use classification. Health Canada has not approved them for human consumption, drug sale, or therapeutic use.
Looking for more peptide research?








